What is behind hepatitis C virus (HCV) drug Harvoni (ledipasvir/sofosbuvir) coming top of a list showing the medicines which accounted for the highest cumulative spending by US patients in 2015?
The drug, marketed by US biotech giant Gilead Sciences (Nasdaq: GILD), led to the most non-discounted spending, according to an IMS Institute for Healthcare Informatics report.
Its list shows that, in total, $14.3 billion was forked out for Harvoni last year, which is more than the combined 2015 totals of Humira (adalimumab) and Sovaldi (sofosbuvir), which were joint-top in the 2014 list.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze